Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) insider Mihael Hristos Polymeropoulos sold 191,760 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now owns 1,031,848 shares of the company’s stock, valued at $15,787,274.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded down $0.05 during trading hours on Thursday, reaching $15.55. The company had a trading volume of 385,547 shares, compared to its average volume of 550,667. The company has a market capitalization of $698.62, a price-to-earnings ratio of -48.59 and a beta of 1.29. Vanda Pharmaceuticals Inc. has a 12 month low of $11.90 and a 12 month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The company had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.01) earnings per share. research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.44 EPS for the current year.
Several equities analysts have recently weighed in on the company. Zacks Investment Research cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 19th. Oppenheimer set a $26.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. BidaskClub raised Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Piper Jaffray Companies lifted their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. Finally, ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $21.50.
TRADEMARK VIOLATION NOTICE: “Vanda Pharmaceuticals Inc. (VNDA) Insider Mihael Hristos Polymeropoulos Sells 191,760 Shares” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/04/vanda-pharmaceuticals-inc-vnda-insider-mihael-hristos-polymeropoulos-sells-191760-shares.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.